Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) have received a consensus rating of “Moderate Buy” from the thirteen ratings firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $29.50.

Several research analysts have recently weighed in on ARCT shares. Wall Street Zen cut shares of Arcturus Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Piper Sandler reduced their target price on shares of Arcturus Therapeutics from $72.00 to $25.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 4th. Citigroup decreased their target price on shares of Arcturus Therapeutics from $66.00 to $21.00 and set a “buy” rating on the stock in a report on Thursday, March 5th. Roth Mkm started coverage on shares of Arcturus Therapeutics in a research note on Thursday, January 22nd. They issued a “buy” rating and a $20.00 price target for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Arcturus Therapeutics in a report on Wednesday, January 21st.

Institutional Investors Weigh In On Arcturus Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ARCT. ARK Investment Management LLC raised its position in Arcturus Therapeutics by 39.4% in the fourth quarter. ARK Investment Management LLC now owns 2,611,099 shares of the biotechnology company’s stock valued at $16,006,000 after purchasing an additional 738,378 shares during the period. Sumitomo Mitsui Trust Group Inc. grew its holdings in shares of Arcturus Therapeutics by 4.0% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,026,588 shares of the biotechnology company’s stock worth $12,423,000 after purchasing an additional 78,753 shares during the period. Amova Asset Management Americas Inc. grew its holdings in shares of Arcturus Therapeutics by 4.0% during the 4th quarter. Amova Asset Management Americas Inc. now owns 2,026,588 shares of the biotechnology company’s stock worth $12,403,000 after purchasing an additional 78,753 shares during the period. Vanguard Group Inc. increased its position in shares of Arcturus Therapeutics by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 1,885,605 shares of the biotechnology company’s stock worth $34,752,000 after purchasing an additional 75,440 shares during the last quarter. Finally, Bank of America Corp DE increased its position in shares of Arcturus Therapeutics by 112.0% during the 3rd quarter. Bank of America Corp DE now owns 620,055 shares of the biotechnology company’s stock worth $11,428,000 after purchasing an additional 327,626 shares during the last quarter. Institutional investors and hedge funds own 94.54% of the company’s stock.

Arcturus Therapeutics Stock Performance

Shares of Arcturus Therapeutics stock opened at $6.72 on Friday. The business’s 50 day moving average price is $7.42 and its 200 day moving average price is $10.59. The company has a market cap of $191.00 million, a price-to-earnings ratio of -2.82 and a beta of 2.40. Arcturus Therapeutics has a one year low of $5.85 and a one year high of $24.17.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its earnings results on Tuesday, March 3rd. The biotechnology company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by ($0.11). Arcturus Therapeutics had a negative net margin of 80.19% and a negative return on equity of 29.13%. The company had revenue of $7.20 million during the quarter, compared to analysts’ expectations of $14.32 million. On average, analysts predict that Arcturus Therapeutics will post -2.22 EPS for the current fiscal year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.